Shire PLC (NASDAQ:SHPG) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 3,854,721 shares, a growth of 38.7% from the November 15th total of 2,779,249 shares. Based on an average daily volume of 1,385,919 shares, the short-interest ratio is currently 2.8 days.

Large investors have recently modified their holdings of the company. YorkBridge Wealth Partners LLC lifted its stake in shares of Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 317 shares during the period. BB&T Investment Services Inc. lifted its stake in shares of Shire by 1,672.3% in the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Shire in the 2nd quarter worth approximately $171,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Shire in the 3rd quarter worth approximately $159,000. Finally, Stephens Inc. AR lifted its stake in shares of Shire by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 228 shares during the period. 20.27% of the stock is owned by institutional investors.

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Royal Bank of Canada reissued a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Liberum Capital raised shares of Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. FBR & Co reissued a “buy” rating and issued a $201.00 target price on shares of Shire in a research report on Monday, October 30th. Finally, Cowen set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. Shire has an average rating of “Buy” and an average target price of $212.18.

Shire (SHPG) opened at $147.20 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The stock has a market cap of $44,510.00, a PE ratio of 10.28, a price-to-earnings-growth ratio of 0.83 and a beta of 1.59. Shire has a one year low of $137.17 and a one year high of $192.15.

Shire (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The firm had revenue of $3.70 billion during the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm earned $3.17 earnings per share. equities research analysts predict that Shire will post 15 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/14/shire-plc-shpg-sees-large-increase-in-short-interest.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.